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Abstracts / Biol Blood Marrow Transplant 20 (2014) S27eS44S34donor RTL remained a statistically signiﬁcant predictor for
recipient survival (HR¼0.63, 95% CI¼0.45-0.87, p¼0.006 for
longest tertile compared to the intermediate and shortest
tertiles)(ﬁg). There was no signiﬁcant interaction between
donor RTL and the patient’s underlying disease. Results were
similar when the analysis was limited to the severe aplastic
anemia group.
Conclusions: Our data suggest that longer donor telomere
lengths are signiﬁcantly associated with improved OS after
HCT for marrow failure syndromes, independent of donor
age. Additional studies of post-HCT donor telomere
dynamics are required to further explain this observation.17
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Reduced intensity conditioning (RIC) HSCT is a potentially
curative therapy for Myeloﬁbrosis (MF), but graft failure is a
major cause of treatment failure. We evaluated the outcomes
and risk factors for graft failure and survival in patients un-
dergoing RIC HSCT. We performed a retrospective review of
all patients receiving a ﬁrst RIC HSCT for MF at Dana Farber
Cancer Institute/Brigham and Women’s Hospital between
January 1, 2000 and December 31, 2012. Primary graft failure
(PGF) was deﬁned as the inability to achieve an ANC greater
than 0.5x109/L for three consecutive days. Secondary failure
was deﬁned as achievement of WBC engraftment with sub-
sequent decline in chimerism to <50%, or need for donor
lymphocyte infusion (DLI) or second HSCT. An event was
deﬁned as primary or secondary graft failure or relapse.
Median age of the cohort (n¼ 40) was 62 years (44-73). The
RIC regimens included ﬂudarabine/IV busulfan 3.2 mg/kg
(Flu/Bu1) (24), ﬂudarabine/IV busulfan 6.4 mg/kg (Flu/Bu2)
(15), or ﬂudarabine/melphalan (1). A majority of patients
received tacrolimus, sirolimus and methotrexate (24) for
GVHD prophylaxis. Nine patients received ATG as part of the
conditioning. All received PBSC except one who received a
dUCBT. Thirty-four patients received 10/10 matched trans-
plants from related or unrelated donors. Eighteen patientsFigure 1.(45%) experienced graft failure including one patient with
PGF. 22.5% of all patients had D30 and 35% had D100
chimerism<50%. Unplanned DLI were needed in 12/40 (30%)
patients. Seven patients (17.5%) ultimately needed a second
transplant for persistent disease and/or poor chimerism.
Grade II-IV acute GVHD incidence at D180 was 18%. Chronic
GVHD incidence at 2 years was 27%. With median follow-up
of 28months, the 2-year EFS and OSwere 29% and 51%. Based
on univariate analysis, use of ATG (p¼0.03), female recipient
gender (p¼0.03), andWBC<5K at transplant (p¼0.016) were
associated with longer EFS, while predictors for superior OS
were absence of circulating blasts (p¼0.004), low platelet
count (p¼0.011) and unrelated donor (p¼0.03). DIPSS score
and spleen size did not predict for EFS or OS. There was a
trend toward improved 2-year OS in patients who received
Flu/Bu2 compared to those who received Flu/Bu1 (53% vs.
21%, p¼ 0.10). We developed a prognostic score based on
factors found to be signiﬁcant on univariate analysis. Based
on this composite score incorporating 1 point for platelet
count>100x109/L, blast count>5%, and non-MUD donor, the
2-year EFS was 49% for score<¼1 and 12% for score>¼2
(p¼0.0017); the 2-year OS was 67% for score<¼1 and 21% for
score>¼2 (p¼0.0003) (Figure 1). RIC HSCT using low dose
Flu/Bu is associated with a high incidence of mixed chime-
rism and late graft failure necessitating frequent unplanned
DLI or second HSCT. The incidence of graft failure may be
mitigated by increasing the intensity of the conditioning
regimen or addition of ATG.18
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Measurement of minimal residual disease (MRD) and the
analysis of chimerism after hematopoietic stem cell trans-
plantation (HSCT) have been used for the detection of
impending relapse. Here, we present the clinical relevance of
both methods. We investigated MRD in 135 consecutive
children with ALL (n¼62), AML (n¼42), MDS (n¼24), or CML
(n¼7) who underwent HSCT. The Wilms’ tumor gene (WT1)
expression was used for the detection of MRD because WT1
is overexpressed in the vast majority of patients with leu-
kemia. For the present study, we investigated if the MRD
status prior to HSCT has any prognostic value. We observed a
signiﬁcantly reduced cumulative incidence of relapse (7%
versus 48%; p<0.001) and a signiﬁcantly increased 5-year
event-free survival (84% versus 35%; p<0.001) in patients
who were MRD negative before transplantation. All 99 pa-
tients who were continuously MRD negative remained in
complete remission at a median of 2432 days after HSCT. In
contrast, all 34 patients who suffered from hematological
relapse after a median of 167 days presented with high levels
of WT1 gene expression (p<0.001). In 21 patients, we
observed an increase ofWT1 expression levels at a median of
31 days before hematological relapse. In 17 of these 21 pa-
tients, DNA was available at the time of increase of WT1
expression level to perform analysis of hematopoietic
chimerism using a quantitative short-tandem-repeat PCR.
Interestingly, only 9 of the 17 patients (53%) showed a mixed
chimerism, whereas 8 of the 17 patients (47%) revealed a
complete donor chimerism. In the remaining 13 patients
with relapse, no increase of WT1 expression levels could be
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harvest and hematological relapse was to long (median, 71
days). In ﬁve of these patients, DNAwas available at the time
of the last sample harvest before relapse and showed a
complete donor chimerism. In two patients, we diagnosed a
molecular relapse using WT1 gene expression. At that time,
both children revealed a complete donor chimerism. In both
patients, long-term molecular remission was achieved by
immunotherapy. In conclusion, quantitative analysis of WT1
gene expression is a valuable tool for monitoring of MRD
before and after HSCT. This approach is very useful for early
diagnosis and treatment of molecular relapse after HSCT.
MRD measurement using WT1 gene expression is more
sensitive for the detection of impending relapse than the
analysis of chimerism.
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Adult umbilical cord blood (UCB) transplant has emerged as
an important option for patients lacking matched related
(MRD) and matched unrelated donors (MUD). Numerous
studies have demonstrated comparable overall survival (OS)
between these donor sources as well as decreased classic
chronic GVHD (cGVHD) following UCB transplantation as
compared to MUD. We compared cGVHD incidence and
immunosuppression burden in consecutive patients under-
going UCB (n¼29) versus peripheral blood MUD transplant
(n¼51) at our center between June 2009 and February 2013.
NIH consensus criteria were used to grade cGVHD. Among
UCB patients, median age at transplant was 49 (range 22-71)
versus 55 (range 18-72) among MUDs. Twelve UCB patients
underwent myeloablative conditioning and 17 patients un-
derwent non-myeloablative (NMA) conditioning for acute
leukemia (n¼17), MDS (n¼5), CLL (n¼2), NHL (n¼4), and CML
(n¼1).GVHDprophylaxiswasCSAandMMF. Forty-eightMUD
patients were 10/10 matched and three patients were 8/8
matched (DQ mismatched). Seventeen patients underwent
myeloablative conditioning (TAC/MTX GVHD prophylaxis)
and 34 patients underwent NMA conditioning (TAC/MMF
GVHD prophylaxis) for acute leukemia (n¼19), NHL (n¼15),MDS (n¼6), CLL (n¼4), Other (n¼6). At two years post-
transplant, cumulative incidence (CI) of moderate to severe
cGVHD was 30% following MUD versus 7% following UCB
(p¼0.02). Among patients not experiencing competing risks
of relapse or transplant relatedmortality (TRM) prior to onset
of cGVHD, median time to being off immunosuppressionwas
307 days among UCB patients (n¼15) versus not reached
among MUD patients (n¼33) (p<0.001). Among 15 UCB pa-
tients, one patient remains on immunosuppression (227 days
post-transplant). Twopatients restarted immunosuppression
due to recrudescent symptoms, but both patients subse-
quently tapered again and remain off immunosuppression.
All 15 patients remain alive. Among 33 MUD patients, seven
patients stopped immunosuppression and four subsequently
restarted for recrudescent GVHD symptoms. All four remain
on immunosuppressive therapy. Five of the 33 patients sub-
sequently died of complications related toGVHD. One year OS
is not signiﬁcantly different between UCB and MUD patients
(65% UCB versus 67% MUD). Cumulative incidence of relapse
and TRM are also non-signiﬁcant comparing UCB and MUD
patients (one year CI relapse 21% UCB versus 17% MURD, CI
TRM 11% UCB versus 17% MUD). These data conﬁrm the low
incidence of classic cGVHD following CBT. We demonstrate a
markedly lower immunosuppression burden following UCB
versus MUD transplant without decreased OS, increased
relapse, or TRM. Combined with the rapid availability of UCB,
this ﬁnding has led our center tomove primarily toUCBwhen
a MRD is not available. Assessment of early and late costs of
transplant using this donor selection approach is ongoing.20
Value of a Consensus Panel to Adjudicate Cause-Speciﬁc
Mortality after Unrelated Donor Allogeneic
Hematopoietic Cell Transplantation (URD-HCT) for Use As
the Primary Endpoint in a Genome-Wide Association
Study (GWAS)
Theresa Hahn 1, Lara Sucheston-Campbell 2, Leah Preus 2,
Kenan Onel 3, Xiaochun Zhu 4, Song Liu 5, Li Yan 5,
David Tritchler 6, Marcelo C. Pasquini 7, Philip L. McCarthy 1.
1Medicine, Roswell Park Cancer Institute, Buffalo, NY; 2Cancer
Prevention and Control, Roswell Park Cancer Institute, Buffalo,
NY; 3Pediatrics, University of Chicago, Chicago, IL; 4CIBMTR,
Medical College of Wisconsin, Milwaukee, WI; 5Biostatistics &
Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY;
6Biostatistics, SUNY University at Buffalo, Buffalo, NY; 7CIBMTR,
CIBMTR/Medical College of Wisconsin, Milwaukee, WI
Cause-speciﬁc death (CSD) due to transplant-related com-
plications (TRM) after URD-HCT is often multi-factorial.
Consensus adjudication panels (CP), commonly used in
clinical trials, are rarely used in observational research. Given
the risk of endpoint misclassiﬁcation due to CSD complexity
